Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches are
beginning to be integrated into drug development and approval processes because they …

The vascularization of engineered tissues and organoids has remained a major unresolved
challenge in regenerative medicine. While multiple approaches have been developed to …

Sažetak Determination of metabolic profiles of new chemical entities is a key step in the
process of drug discovery, since it influences pharmacokinetic characteristics of therapeutic …

Small peptides with a molecular weight of< 2 kDa represent a performance-enhancing
substances. However, in vivo studies with human volunteers are limited because most of …

Cytochrome P450 enzyme variant alleles have shown evidence that functional
consequences differ between substrates. A systematic effort has not yet been made to …

Polypharmacy increases the risk of drug–drug interactions (DDIs). Combining
epidemiological studies with pharmacokinetic modeling, we detected and evaluated high …

The key parameters necessary to predict drug‐drug interactions (DDIs) are intrinsic
clearance (CLint) and fractional contribution of the metabolizing enzyme toward total …

Primary hepatocytes offer a simple in vitro model for studying biotransformation of drugs or
novel chemical entities. The utility of hepatocytes for the prediction of in vivo clearance was …

Physiologically-based pharmacokinetic (PBPK) modeling and simulation have become an
integral part of the drug development process. This approach is a mathematical technique …

Pseudomonas aeruginosa is an opportunistic human pathogen responsible for a large
proportion of drug-resistant, hospital-acquired infections worldwide. These infections are …